Compare MCS & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCS | ENTA |
|---|---|---|
| Founded | 1935 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.7M | 486.3M |
| IPO Year | 1994 | 2012 |
| Metric | MCS | ENTA |
|---|---|---|
| Price | $17.39 | $13.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $23.75 | $20.40 |
| AVG Volume (30 Days) | 132.2K | ★ 184.0K |
| Earning Date | 05-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.82% | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $758,458,000.00 | $102,814,000.00 |
| Revenue This Year | $11.78 | $5.91 |
| Revenue Next Year | $3.09 | N/A |
| P/E Ratio | $22.84 | ★ N/A |
| Revenue Growth | 3.11 | ★ 16.48 |
| 52 Week Low | $12.85 | $4.09 |
| 52 Week High | $18.80 | $17.15 |
| Indicator | MCS | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 67.21 | 44.83 |
| Support Level | $16.66 | $13.39 |
| Resistance Level | $18.09 | $13.98 |
| Average True Range (ATR) | 0.64 | 0.86 |
| MACD | 0.14 | -0.03 |
| Stochastic Oscillator | 78.52 | 15.79 |
Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.